Vertex announces publication in the new england journal of medicine of phase 3 results for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis

Boston--(business wire)--the new england journal of medicine published results from a ph 3 study of trikafta® in people with cystic fibrosis ages 12 and older.
VRTX Ratings Summary
VRTX Quant Ranking